Lyell Immunopharma (NASDAQ:LYEL) Announces Quarterly Earnings Results, Misses Expectations By $0.52 EPS

Lyell Immunopharma (NASDAQ:LYEL) announced its quarterly earnings results on Tuesday. The company reported ($0.72) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.52), Zacks reports. Lyell Immunopharma had a negative net margin of 323,792.09% and a negative return on equity of 34.64%. The company had revenue of $0.01 million during the quarter.

Lyell Immunopharma Trading Down 2.3 %

NASDAQ LYEL opened at $0.67 on Wednesday. Lyell Immunopharma has a 1-year low of $0.51 and a 1-year high of $3.15. The company has a 50 day moving average of $0.63 and a 200-day moving average of $0.93. The firm has a market cap of $194.49 million, a price-to-earnings ratio of -0.84 and a beta of -0.41.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “neutral” rating and issued a $1.00 target price on shares of Lyell Immunopharma in a research note on Tuesday, November 12th.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.